Global Anti-Epileptic Drugs Market to be Worth Nearly US$ 4,458.0 Million by 202
Posted by Nikita Manwar on October 5th, 2019
GMI Research has published a new study titled “Global Anti-Epileptic Drugs Market, By Spectrum Type (Narrow Spectrum and Broad Spectrum), By Drug (Phenytoin, Phenobarbital, Carbamazepine, Oxcarbazepine, Gabapentin, Pregabalin, Lacosamide, Vigabatrin, Valproic Acid, Lamotrigine, Topiramate, Zonisamide, Levetiracetam, Clonazepam, Rufinamide) and Geography – Opportunities & Forecast, 2019-2026”, which orates the future prospects set to strike the Anti-Epileptic Drugs Market during the forecast period.
The Global Anti-Epileptic Drugs Market was valued at USD 3,323.7 million in 2018, and is projected to reach USD 4,458.0 million by 2026, growing at a CAGR of 3.8% during 2019-2026. Alcoholism, smoking, Dietary habits and rising geriatric population are the major factor driving the antiepileptic drugs market. Additionally, wide availability of technically advanced Anti-Epileptic Drugs, improvement in diagnosis and treatment of epilepsy and rising demand for home based Anti-Epileptic Drugs treatment are likely to push the growth of global Anti-Epileptic Drugs market in the forecast years.
Antiepileptic drug can also be known as anti-seizure drug, developed for asymptomatic and Idiopathic treatment of epilepsy and seizures. Antiepileptic drugs can also be used for the treatment of neuropathic pain. Causes of epilepsy seizures are not defined or undetermined which has led many Antiepileptic drugs approved in the past years. Major factors which causes epilepsy include brain injury, stroke, and substance use disorders. Treatment of epilepsy, antiepileptic drugs or medicines (AEDs) are prescribed based on age of the patient, type of seizures to be treated, and which part of the brain is involved.
Based on Drug Valporic Acid (salt) is anticipated to lead the market during 2019-2026
North America held the largest market share in global Anti-Epileptic Drugs market in 2018 owing to increasing social awareness, social acceptance, awareness among the population and government and private players inclination on Anti-Epileptic Drugs issues. Rest of the World is predicted to be the attractive regional market in global Anti-Epileptic Drugs market and is likely to show the maximum growth in the next few years.
Various notable players operating in global Anti-Epileptic Drugs market include Abbott Laboratories, Cephalon, Inc, Sunovion Pharmaceuticals, Valeant Pharmaceuticals International, Sanofi S.A, UCB Pharma Ltd, GlaxoSmithKline plc, Johnson & Johnson, Novartis, AG, Pfizer Inc among others.
The Global Anti-Epileptic Drugs Market has been segmented on the basis of spectrum type, drug type, and key geographies. Based on spectrum type, the market comprises of Narrow Spectrum and Broad Spectrum. The drug type includes Phenytoin, Phenobarbital, Carbamazepine, Oxcarbazepine, Gabapentin, Pregabalin, Lacosamide, Vigabatrin, Valproic Acid, Lamotrigine, Topiramate, Zonisamide, Levetiracetam, Clonazepam, Rufinamide
Key questions answered in this research report:
By Spectrum type
About GMI Research
GMI Research is a market research and consulting firm which provides research-based solutions to business executives and investment professionals so that they can make right business & investment decisions faster based on real facts. We help business leaders through independent fact-based insight, ensuring their business achieve success by beating the competition.
GMI Research leverages its industry expertise and experience to identify the industry trends, big opportunities and potential growth areas across industries. Our Syndicated reports provide actionable insights and covers industry trends, market drivers & restraints, macroeconomics factors, market estimates & forecasts, competitive landscape etc. which helps our clients to strengthen its market position by deploying specific strategies and actions that will lead to higher growth.
Like it? Share it!
About the AuthorNikita Manwar
Joined: September 10th, 2019
Articles Posted: 80
More by this author